Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

Anti-tumor activity evaluation of novel tubulin and HDAC dual-targeting inhibitors.

Wang B, Chen X, Gao J, Su L, Zhang L, Xu H, Luan Y.

Bioorg Med Chem Lett. 2019 Sep 15;29(18):2638-2645. doi: 10.1016/j.bmcl.2019.07.045. Epub 2019 Jul 24.

PMID:
31400938
2.

Design, synthesis and biological evaluation of novel hydroxamates and 2-aminobenzamides as potent histone deacetylase inhibitors and antitumor agents.

Xie R, Yao Y, Tang P, Chen G, Liu X, Yun F, Cheng C, Wu X, Yuan Q.

Eur J Med Chem. 2017 Jul 7;134:1-12. doi: 10.1016/j.ejmech.2017.03.038. Epub 2017 Mar 22.

PMID:
28391133
3.

Novel histone deacetylase inhibitors bearing a 4-piperidin-4-yl-triazole scaffold as antitumor agents.

Wang Y, Su L, Wang Q, Zhang L, Luan Y.

Drug Dev Res. 2019 Oct 3. doi: 10.1002/ddr.21603. [Epub ahead of print]

PMID:
31580523
4.

Spirohydantoins and 1,2,4-triazole-3-carboxamide derivatives as inhibitors of histone deacetylase: Design, synthesis, and biological evaluation.

Aboeldahab AMA, Beshr EAM, Shoman ME, Rabea SM, Aly OM.

Eur J Med Chem. 2018 Feb 25;146:79-92. doi: 10.1016/j.ejmech.2018.01.021. Epub 2018 Jan 12.

PMID:
29396364
5.

A Novel Dual HDAC6 and Tubulin Inhibitor, MPT0B451, Displays Anti-tumor Ability in Human Cancer Cells in Vitro and in Vivo.

Wu YW, Hsu KC, Lee HY, Huang TC, Lin TE, Chen YL, Sung TY, Liou JP, Hwang-Verslues WW, Pan SL, HuangFu WC.

Front Pharmacol. 2018 Mar 13;9:205. doi: 10.3389/fphar.2018.00205. eCollection 2018.

6.

Effects of novel HDAC inhibitors on urothelial carcinoma cells.

Kaletsch A, Pinkerneil M, Hoffmann MJ, Jaguva Vasudevan AA, Wang C, Hansen FK, Wiek C, Hanenberg H, Gertzen C, Gohlke H, Kassack MU, Kurz T, Schulz WA, Niegisch G.

Clin Epigenetics. 2018 Jul 31;10(1):100. doi: 10.1186/s13148-018-0531-y.

7.

Class I and class II histone deacetylases are potential therapeutic targets for treating pancreatic cancer.

Wang G, He J, Zhao J, Yun W, Xie C, Taub JW, Azmi A, Mohammad RM, Dong Y, Kong W, Guo Y, Ge Y.

PLoS One. 2012;7(12):e52095. doi: 10.1371/journal.pone.0052095. Epub 2012 Dec 14.

8.

Design and synthesis of novel histone deacetylase 6 inhibitors with benzyl-triazole as the core skeleton.

Mou Z, Gao J, Miao H, Zhang L, Su L, Wang B, Luan Y.

Biosci Trends. 2019 Jul 22;13(3):267-272. doi: 10.5582/bst.2019.01054. Epub 2019 May 31.

9.

Development of hydroxamate-based histone deacetylase inhibitors containing 1,2,4-oxadiazole moiety core with antitumor activities.

Yang F, Shan P, Zhao N, Ge D, Zhu K, Jiang CS, Li P, Zhang H.

Bioorg Med Chem Lett. 2019 Jan 1;29(1):15-21. doi: 10.1016/j.bmcl.2018.11.027. Epub 2018 Nov 14.

PMID:
30455152
10.

Developing selective histone deacetylases (HDACs) inhibitors through ebselen and analogs.

Wang Y, Wallach J, Duane S, Wang Y, Wu J, Wang J, Adejare A, Ma H.

Drug Des Devel Ther. 2017 May 2;11:1369-1382. doi: 10.2147/DDDT.S124977. eCollection 2017.

11.

Design and synthesis of tranylcypromine derivatives as novel LSD1/HDACs dual inhibitors for cancer treatment.

Duan YC, Ma YC, Qin WP, Ding LN, Zheng YC, Zhu YL, Zhai XY, Yang J, Ma CY, Guan YY.

Eur J Med Chem. 2017 Nov 10;140:392-402. doi: 10.1016/j.ejmech.2017.09.038. Epub 2017 Sep 21.

PMID:
28987602
12.

Rational design, synthesis and preliminary antitumor activity evaluation of a chlorambucil derivative with potent DNA/HDAC dual-targeting inhibitory activity.

Xie R, Li Y, Tang P, Yuan Q.

Bioorg Med Chem Lett. 2017 Sep 15;27(18):4415-4420. doi: 10.1016/j.bmcl.2017.08.011. Epub 2017 Aug 8.

PMID:
28818449
13.

5-(Furan-2-yl)-4-(3,4,5-trimethoxyphenyl)-3H-1,2-dithiol-3-one oxime (6f), a new synthetic compound, causes human fibrosarcoma HT-1080 cell apoptosis by disrupting tubulin polymerisation and inducing G2/M arrest.

Zuo D, Pang L, Shen J, Guan Q, Bai Z, Zhang H, Li Y, Lu G, Zhang W, Wu Y.

Int J Oncol. 2017 Jun;50(6):2069-2078. doi: 10.3892/ijo.2017.3963. Epub 2017 Apr 18.

PMID:
28440465
14.

Design, synthesis and biological evaluation of colchicine derivatives as novel tubulin and histone deacetylase dual inhibitors.

Zhang X, Kong Y, Zhang J, Su M, Zhou Y, Zang Y, Li J, Chen Y, Fang Y, Zhang X, Lu W.

Eur J Med Chem. 2015 May 5;95:127-35. doi: 10.1016/j.ejmech.2015.03.035. Epub 2015 Mar 18.

PMID:
25805446
15.

Design, synthesis and biological evaluation of resveratrol-cinnamoyl derivates as tubulin polymerization inhibitors targeting the colchicine binding site.

Yin Y, Lian BP, Xia YZ, Shao YY, Kong LY.

Bioorg Chem. 2019 Sep 26;93:103319. doi: 10.1016/j.bioorg.2019.103319. [Epub ahead of print]

PMID:
31585270
16.

Thioether-based 2-aminobenzamide derivatives: Novel HDAC inhibitors with potent in vitro and in vivo antitumor activity.

Yun F, Cheng C, Ullah S, He J, Zahi MR, Yuan Q.

Eur J Med Chem. 2019 Aug 15;176:195-207. doi: 10.1016/j.ejmech.2019.05.007. Epub 2019 May 10.

PMID:
31103900
17.

A novel small molecule hybrid of vorinostat and DACA displays anticancer activity against human hormone-refractory metastatic prostate cancer through dual inhibition of histone deacetylase and topoisomerase I.

Yu CC, Pan SL, Chao SW, Liu SP, Hsu JL, Yang YC, Li TK, Huang WJ, Guh JH.

Biochem Pharmacol. 2014 Aug 1;90(3):320-30. doi: 10.1016/j.bcp.2014.06.001. Epub 2014 Jun 7.

PMID:
24915421
18.

Design, Synthesis and Biological Evaluation of Novel Coumarin-Based Hydroxamate Derivatives as Histone Deacetylase (Hdac) Inhibitors with Antitumor Activities.

Yang F, Zhao N, Song J, Zhu K, Jiang CS, Shan P, Zhang H.

Molecules. 2019 Jul 15;24(14). pii: E2569. doi: 10.3390/molecules24142569.

19.

The structural requirements of histone deacetylase inhibitors: C4-modified SAHA analogs display dual HDAC6/HDAC8 selectivity.

Negmeldin AT, Knoff JR, Pflum MKH.

Eur J Med Chem. 2018 Jan 1;143:1790-1806. doi: 10.1016/j.ejmech.2017.10.076. Epub 2017 Oct 31.

20.

Design, synthesis, docking studies and biological evaluation of novel chalcone derivatives as potential histone deacetylase inhibitors.

Mohamed MFA, Shaykoon MSA, Abdelrahman MH, Elsadek BEM, Aboraia AS, Abuo-Rahma GEAA.

Bioorg Chem. 2017 Jun;72:32-41. doi: 10.1016/j.bioorg.2017.03.005. Epub 2017 Mar 19.

PMID:
28346873

Supplemental Content

Support Center